Artal Group S.A. Dyne Therapeutics, Inc. Transaction History

Artal Group S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$23.65 - $35.63 $23,650 - $35,630	-1,000 Reduced 0.07%	1,516,960 $53.5 Million
Q1 2024 May 13, 2024	BUY	$13.06 - $29.18 $3.92 Million - $8.75 Million	300,000 Added 24.63%	1,517,960 $43.1 Million
Q4 2023 Feb 09, 2024	BUY	$6.62 - $13.64 $2.67 Million - $5.5 Million	402,875 Added 49.43%	1,217,960 $16.2 Million
Q2 2023 Aug 11, 2023	BUY	$8.53 - $14.28 $2.41 Million - $4.03 Million	282,476 Added 53.04%	815,085 $9.17 Million
Q1 2023 May 12, 2023	BUY	$10.88 - $15.0 $82,785 - $114,135	7,609 Added 1.45%	532,609 $6.14 Million
Q1 2021 May 14, 2021	BUY	$14.0 - $29.3 $3.15 Million - $6.59 Million	225,000 Added 75.0%	525,000 $8.15 Million
Q4 2020 Feb 11, 2021	SELL	$16.81 - $23.94 $1.18 Million - $1.68 Million	-70,000 Reduced 18.92%	300,000 $6.3 Million
Q3 2020 Nov 13, 2020	BUY	$20.0 - $23.9 $7.4 Million - $8.84 Million	370,000 New	370,000 $7.47 Million

207

102M

234K

238K

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $731M
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.